The present disclosure relates to tungsten complexes, catalyst systems including tungsten complexes, and polymerization processes to produce polycycloolefin polymers such as polycyclopentene polymers and polycyclooctene polymers.

In some aspects, the present disclosure provides pharmaceutical compositions comprising a) a therapeutic agent; b) a metal-organic framework (MOF) or a coordination polymer; and c) a pharmaceutically acceptable polymer; wherein the therapeutic agent is encapsulated within the metal-organic framework or coordination polymer to form an encapsulated therapeutic agent, and wherein the encapsulated therapeutic agent is further encapsulated, entrapped, embedded, dispersed within, or complexed to the pharmaceutically acceptable polymer. The present disclosure also provides methods of making said compositions, methods of treating a disease or disorder comprising administering to a subject said compositions. The present disclosure also provides microneedles and implantable medical devices comprising said compositions.

Provided are novel imidazopyrazine derivatives having the general formula (I), wherein A and R.sup.1 to R.sup.14 are as described herein

##STR00001##

and pharmaceutically acceptable salts thereof.

Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Provided are novel imidazopyrazine derivatives having the general formula (I), wherein A and R.sup.1 to R.sup.14 are as described herein

##STR00001##

and pharmaceutically acceptable salts thereof.

Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

A process for producing isomerized olefins, branched aldehydes, branched alcohols, branched surfactants and other branched derivatives through isomerization, hydroformylation, hydrogenation, surfactant forming reactions and other derivative forming reactions.

Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.

A method for producing a carbamic acid salt, including contacting a carbon dioxide-containing mixed gas having a partial pressure of carbon dioxide of 0.001 atm or more and less than 1 atm with an amino group-containing organic compound in the presence of a base in at least one organic solvent selected from the group consisting of an organic solvent having 2 or more and 8 or less carbon atoms, and a method for producing a carbamic acid ester or a urea derivative using the carbamic acid salt.

The purpose of the present invention is to provide a curing catalyst that is highly stable and has a practical curing speed. The present invention provides a curing catalyst [B] used for curing a polymer [A] that has a reactive hydrolyzable silicon-containing group. The curing catalyst [B] contains the reaction products of a metal alkoxide [B1] and an ammonium hydroxide [B2]. The metal alkoxide [B1] includes one or both of a titanium compound [B1a] that is represented by chemical formula (1), and another metal alkoxide [B1b]. The other metal alkoxide [B1b] is an alkoxide of a metal other than titanium, and the ammonium hydroxide [B2] is represented by chemical formula (2).

The purpose of the present invention is to provide a curing catalyst that is highly stable and has a practical curing speed. The present invention provides a curing catalyst [B] used for curing a polymer [A] that has a reactive hydrolyzable silicon-containing group. The curing catalyst [B] contains the reaction products of a metal alkoxide [B1] and an ammonium hydroxide [B2]. The metal alkoxide [B1] includes one or both of a titanium compound [B1a] that is represented by chemical formula (1), and another metal alkoxide [B1b]. The other metal alkoxide [B1b] is an alkoxide of a metal other than titanium, and the ammonium hydroxide [B2] is represented by chemical formula (2).

A method for preparing an aldehyde including forming a reaction product including an aldehyde by reacting an olefin-based compound with a synthetic gas in a hydroformylation reactor in the presence of a hydroformylation catalyst; introducing the reaction product including the aldehyde to a vaporizer; separating low-boiling point components of the reaction product from an upper part of a vaporizer catch pot included in the vaporizer; separating high-boiling point components of the reaction product from a lower part of the vaporizer catch pot; and recirculating at least a portion of the low-boiling point components separated from an upper part of the vaporizer catch pot back to the vaporizer.